iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025

Core Insights - iRhythm Technologies published a study in Heart Rhythm, analyzing data from over 1.1 million patients using its Zio long-term continuous monitoring (LTCM) service, highlighting the importance of long-term monitoring for arrhythmia detection [1][3][4] Group 1: Study Findings - The study revealed that short-term monitoring (24-48 hours) often fails to detect actionable arrhythmias, even in patients reporting daily symptoms, with 64% of daily-symptom patients having undetected arrhythmias within the first 48 hours [3][4] - Less than 20% of patients documented symptoms coinciding with arrhythmic episodes, indicating a low symptom-rhythm correlation [4] - The mean time to first detected arrhythmia exceeded 48 hours for all arrhythmia types, regardless of symptom frequency, emphasizing the clinical value of Zio LTCM for up to 14 days [4][5] Group 2: Real-World Evidence and Compliance - Data presented at the AHA Scientific Sessions 2025 confirmed high compliance and data quality for at-home self-application of Zio LTCM devices, with median wear time exceeding 13.8 days and analyzable ECG time over 98% [6][8] - The MyZio mobile app usage was significantly higher among home-enrolled patients (52% vs. 17%), leading to better compliance and fewer early terminations [8] Group 3: CKM Syndrome Insights - New analyses presented at AHA 2025 revealed that arrhythmias can emerge earlier across the cardio-kidney-metabolic (CKM) syndrome continuum, with 58% of CKD patients experiencing arrhythmias before CKD diagnosis [10][11] - The incidence of arrhythmias increased with CKM stages, highlighting the need for early rhythm assessment in at-risk populations [10][11] Group 4: Company Commitment and Innovations - iRhythm aims to reach the estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias through scalable, clinically validated solutions [13] - The collaboration with Lucem Health focuses on combining ECG monitoring with AI-powered risk stratification to enhance early detection of arrhythmia risk [14] - iRhythm's comprehensive clinical evidence program includes over 125 original research manuscripts and insights from more than 2 billion hours of curated heartbeat data, reinforcing its commitment to improving patient outcomes [15]